Johan M. Spoor Purchases 14,500 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor bought 14,500 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were purchased at an average price of $3.78 per share, with a total value of $54,810.00. Following the transaction, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. This represents a 10.54 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $3.69 on Tuesday. The company has a fifty day moving average price of $11.33. Perspective Therapeutics, Inc. has a 52 week low of $2.28 and a 52 week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Analysts forecast that Perspective Therapeutics, Inc. will post -0.86 EPS for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors have recently modified their holdings of CATX. nVerses Capital LLC acquired a new position in Perspective Therapeutics in the third quarter valued at approximately $57,000. US Bancorp DE raised its position in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Perspective Therapeutics during the 2nd quarter valued at $117,000. Point72 DIFC Ltd bought a new position in shares of Perspective Therapeutics in the 2nd quarter worth $118,000. Finally, Intech Investment Management LLC bought a new position in shares of Perspective Therapeutics in the 3rd quarter worth $137,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Analysts Set New Price Targets

CATX has been the topic of several research analyst reports. Royal Bank of Canada decreased their price objective on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Truist Financial started coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective for the company. Wedbush restated an “outperform” rating and set a $11.00 target price (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Finally, Oppenheimer lowered their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Perspective Therapeutics has an average rating of “Moderate Buy” and an average target price of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.